Show simple item record

dc.contributor.authorMartinez-Roman, Paula 
dc.contributor.authorCrespo-Bermejo, Celia 
dc.contributor.authorValle-Millares, Daniel 
dc.contributor.authorLara-Aguilar, Violeta 
dc.contributor.authorArca de Lafuente, Sonia 
dc.contributor.authorMartín-Carbonero, Luz
dc.contributor.authorRyan, Pablo
dc.contributor.authorde Los Santos, Ignacio
dc.contributor.authorLopez-Huertas, Maria Rosa 
dc.contributor.authorPalladino, Claudia
dc.contributor.authorMuñoz-Muñoz, María
dc.contributor.authorFernandez-Rodriguez, Amanda 
dc.contributor.authorCoiras, Mayte 
dc.contributor.authorBriz, Veronica 
dc.contributor.authorCOVIHEP network
dc.date.accessioned2022-12-20T13:05:14Z
dc.date.available2022-12-20T13:05:14Z
dc.date.issued2022-06-21
dc.identifier.citationJ Clin Med. 2022 Jun 21;11(13):3579.es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15294
dc.description.abstractBackground: Although human immunodeficiency virus type 1 (HIV-1) reservoir size is very stable under antiretroviral therapy (ART), individuals exposed to the Hepatitis C virus (HCV) (chronically coinfected and spontaneous clarifiers) show an increase in HIV reservoir size and in spliced viral RNA, which could indicate that the viral protein regulator Tat is being more actively synthesized and, thus, could lead to a higher yield of new HIV. However, it is still unknown whether the effect of HCV elimination with direct-acting antivirals (DAAs) could modify the HIV reservoir and splicing. Methods: This longitudinal study (48 weeks' follow-up after sustained virological response) involves 22 HIV+-monoinfected individuals, 17 HIV+/HCV- spontaneous clarifiers, and 24 HIV+/HCV+ chronically infected subjects who eliminated HCV with DAAs (all of them aviremic, viral load < 50). Viral-spliced RNA transcripts and proviral DNA copies were quantified by qPCR. Paired samples were analyzed using a mixed generalized linear model. Results: A decrease in HIV proviral DNA was observed in HIV+/HCV- subjects, but no significant differences were found for the other study groups. An increased production of multiple spliced transcripts was found in HIV+ and HIV+/HCV+ individuals. Conclusions: We conclude that elimination of HCV by DAAs was unable to revert the consequences derived from chronic HCV infection for the reservoir size and viral splicing, which could indicate an increased risk of rapid HIV-reservoir reactivation. Moreover, spontaneous clarifiers showed a significant decrease in the HIV reservoir, likely due to an enhanced immune response in these individuals.es_ES
dc.description.sponsorshipFinancial support was provided by the Instituto de Salud Carlos III to V.B. and A.F.-R. (PI15CIII/00031 and PI18CIII/00020) and the SPANISH AIDS Research Network (RD16CIII/0002/0001 and RD16CIII/0002/0002—ISCIII—FEDER). A.F.-R. is supported by the Miguel Servet program from Fondo de Investigación Sanitaria (ISCIII) (CP14/CIII/00010). Financial support was provided by the National Institutes of Health (NIH) (Grant R01AI143567) for M.C. The work of M.R.L.-H. is financed by the NIH (Grant R01AI143567). C.P. is funded by FCT—Fundação para a Ciência e a Tecnologia, I.P. (national funding), under a contract program as defined by DL No. 57/2016 and Law No. 57/2017.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDAAses_ES
dc.subjectHIV reservoires_ES
dc.subjectHIV/HCVes_ES
dc.subjectCoinfectiones_ES
dc.subjectDynamicses_ES
dc.subjectSpontaneous HCV clearancees_ES
dc.subjectViral splicinges_ES
dc.titleDynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearancees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35806864es_ES
dc.format.volume11es_ES
dc.format.number13es_ES
dc.format.page3579es_ES
dc.identifier.doi10.3390/jcm11133579es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderFundação para a Ciência e Tecnologia (Portugal) es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm11133579es_ES
dc.identifier.journalJournal of Clinical Medicinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI15CIII/00031es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2018)/PI18CIII/00020es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002-ISCIII-FEDERes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP14/CIII/00010es_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional